FOR IMMEDIATE RELEASE

NEUROCOG TRIALS CEO PRESENTS LATEST DATA USING STATE OF THE ART COGNITION BATTERY IN SCHIZOPHRENIA CLINICAL TRIAL

Talk to be Part of Presentation at International Society for CNS Clinical Trials & Methodology

DURHAM, NORTH CAROLINA, October 13, 2010 – NeuroCog Trials, Inc. announces that Richard Keefe, Ph.D., Founder and CEO of NeuroCog Trials, was a featured speaker at the Autumn Conference of the International Society for CNS Clinical Trials and Methodology (ISCTM). Dr. Keefe’s presentation ‘Real-World Application of the MATRICS Consensus Cognitive Battery in Multisite Clinical Trials’ was an element of the session ‘MATRICS Update and Beyond’.

Dr. Keefe said “The initial validation studies of the state of the art MATRICS Cognitive Consensus Battery (MCCB), completed during the MATRICS contract with NIMH, clearly demonstrated its test-retest reliability, small practice effects, correlations with measures of functional capacity, practicality and tolerability. However, it has been an empirical question whether the MCCB would demonstrate these favorable characteristics when administered in the context of a large multi-site industry trial for which it was designed.”

Dr. Keefe reviewed seven recent schizophrenia cognition trials that used the MCCB as a primary outcome measure and followed MATRICS study design guidelines. Results demonstrated excellent test-retest reliabilities, low missing data rates, small practice effects and excellent sensitivities to cognitive impairment. Dr. Keefe emphasized that “these studies included two international trials using non-English translations of the MCCB, over 1100 patients in all. The results from these separate trials suggest that the MCCB is a robust measure of cognition in schizophrenia for multisite clinical trials.”

About NeuroCog Trials

NeuroCog Trials Inc. is the leading cognition services company for the pharmaceutical industry. NeuroCog Trials provides consulting, site screening, rater training and certification, and data review services to clinical trials. Our mission is to facilitate the development of novel therapies to enhance cognition. We bring to all of our work deep expertise, strategic innovation, and an unwavering commitment to research excellence.

For more information on NeuroCog Trials, its services, and licensing inquiries for its exclusive neuropsychological and functional capacity assessment batteries, please see www.neurocogtrials.com.

###